| AHRQ | Agency for Healthcare Research and Quality (United States) |
| AIFA | Agenzia Italiana del Farmaco (Italian Medicines Agency) |
| AMC | Advance market commitment |
| AMR | Anti-microbial resistance |
| APEC-LSIF | Asia-Pacific Economic Cooperation - Life Sciences Innovation Forum |
| ASM | United States Census Annual Survey of Manufacturing |
| ASP | Average sales price (United States) |
| AUD | Australian dollars |
| AZT | Zidovudine also known as azidothymidine |
| BERD | Business Enterprise Expenditure on R&D |
| BRDIS | Business R&D and Innovation Survey |
| CAPM | Capital Asset Pricing Model |
| CDF | Cancer Drug Fund (United Kingdom) |
| CEA | Cost effectiveness analysis |
| CED | Coverage with evidence development |
| CEESTAHC | Central & Eastern European Society of Technology Assessment in Health Care |
| CEPS | Comité économique des produits de santé (Economic Committee for Health Products, France) |
| CML | Chronic myeloid leukaemia |
| CMS | Centers for Medicare & Medicaid Services (United States) |
| CoE | Cost of Equity |
| CoK | Cost of Capital |
| COMET | Core Outcome Measures in Effectiveness Trials |
| COMP | Committee on Orphan Medicinal Products (EMA) |
| DAA | Direct acting anti-viral |
| DALY | Disability-Adjusted Life Years |
| DDD | Defined daily dose |
| DMARD | Biological Disease-Modifying Anti-Rheumatic Drug |
| DMT | Disease Modifying Therapy |
| DNDi | Drugs for Neglected Diseases Initiative |
| DRG | Diagnosis-related group |
| ECDS | Eastern Caribbean Drug Service |
| EEA | European Economic Area |
| EFPIA | European Federation of Pharmaceutical Industries & Associations |
| EHR | Electronic health record |
| EHRRG | Electronic Health Records Research Group |
| EMA | European Medicines Agency |
| ESMO | European Society for Medical Oncology |
| ESRD | End stage renal disease |
| EU | European Union |
| EUnetHTA | European Network for Health Technology Assessment |
| EUR | Euro |
| FDA | Food & Drug Administration (US) |
| FFS | Fee for Service |
| FOSYGA | Fondo de Solidaridad y Garantia (Colombian Solidarity and Guarantee Fund) |
| FTEs | Full-time equivalents |
| GBP | Pounds Sterling |
| GCC/GPP | Gulf Cooperation Council / Group Purchasing Program |
| GDF | Global Drug Facility |
| GDP | Gross domestic product |
| GICS | Global Industry Classification Standard |
| GP | General practitioner |
| GVA | Gross value added |
| HAS | Haute Autorité de Santé (France) |
| HCV | Hepatitis C virus |
| HIV/AIDS | Human immunodeficiency virus/acquired immunodeficiency syndrome |
| HS | Horizon scanning |
| HTA | Health technology assessment |
| HTAi | Health Technology Assessment International |
| ICER | Incremental cost-effectiveness ratio |
| ICH | International Conference on Harmonization |
| ICT | Information and communications technology |
| ICTRP | International Clinical Trials Registry Platform |
| IGDRP | International Generic Drug Regulators Programme |
| IHSP | Italian Horizon Scanning Project |
| IMI | Innovative Medicines Initiative |
| INAHTA | International Network of Agencies for Health Technology Assessment |
| INN | International non-proprietary name |
| IPRP | International Pharmaceutical Regulators Programme |
| KCE | Federaal Kenniscentrum voor de gezondheidszorg (Belgian Healthcare Knowledge Centre) |
| LCA | Least costly alternative |
| LIS | Legemiddleinnkjøpssamarbeid (Norwegian Drug Procurement Cooperation) |
| LMICs | Low- and middle-income countries |
| LoE | Loss of exclusivity |
| LSDP | Life Saving Drugs Program (Australia) |
| MA-PD | Medicare Advantage - Prescription Drug plan (United States) |
| MCDA | Multi-criteria decision analysis |
| MEA | Managed entry agreement |
| MPP | Medicines Patent Pool |
| MRFF | Medical Research Future Fund (Australia) |
| NAICS | North American Industry Classification System |
| NAS | New active substance |
| NCE | New chemical entity |
| NDA | New drug approval |
| NGO | Non-government organisation |
| NHS | National Health Service (United Kingdom) |
| NICE | National Institute for Health & Care Excellence (United Kingdom) |
| NIH | National Institutes of Health (United States) |
| NIHR | National Institute for Health Research (United Kingdom) |
| NME | New molecular entity |
| NOK | Norwegian Krone |
| NPV | Net present value |
| NSF | National Science Foundation |
| NTD | Neglected tropical disease |
| OECD | Organisation for Economic Co-operation & Development |
| OFT | Office of Fair Trading (United Kingdom) |
| OHDS | Observational Health Data Sciences and Informatics |
| OMPs | Orphan medical products |
| OTC | Over the counter |
| P&T | Pharmacy and therapeutics |
| P4P | Pay for performance |
| PAH | Pulmonary arterial hypertension |
| PAHO | Pan American Health Organisation |
| PANDRH | Pan American Network for Drug Regulatory Harmonization |
| PaRR | Policy and Regulatory Report database |
| PBAC | Pharmaceutical Benefits Advisory Committee (Australia) |
| PBM | Pharmacy benefit manager |
| PBS | Pharmaceutical Benefits Scheme (Australia) |
| PhRMA | Pharmaceutical Research and Manufacturers of America |
| PMDA | Pharmaceuticals & Medical Devices Agency (Japan) |
| PDP | Product development partnership |
| PFS | Progression-free survival |
| PPP | Public-private partnership |
| PPRI | Pharmaceutical Pricing & Reimbursement Information |
| PPRS | Pharmaceutical Price Regulation Scheme (United Kingdom) |
| QALY | Quality-Adjusted Life Year |
| R&D | Research and development |
| RCT | Randomised controlled trial |
| RedESTA | Red de Evaluación de Tecnologías en Salud de Las Américas (Health Technology Assessments Network for the Americas) |
| RFP | Request for proposal |
| RFT | Request for tender |
| RoA | Return on assets |
| SEK | Swedish Krona |
| SME | Small and medium-sized enterprises |
| SNA | System of National Accounts |
| SOF/LDV | sofosbuvir /ledipasvir |
| SOF/VEL | sofosbuvir/velpatasvir |
| SPA | Special protocol assessment |
| SRA | Stringent regulatory agency |
| SRDR | Systematic Review Data Repository |
| STAN | Structural Analysis |
| SVR | Sustained viral response |
| TFEU | Treaty on the Functioning of the European Union |
| TKI | Tyrosine kinase inhibitor |
| TLV | The National Dental and Pharmaceutical Benefits Agency (Sweden) |
| TNF | Tumour necrosis factor |
| UKPDS | United Kingdom Prospective Diabetes Study |
| USD | United States dollars |
| VHI | Voluntary health insurance |
| WAC | Wholesale acquisition cost (United States) |
| WHO | World Health Organization |
| WIPO | World Intellectual Property Organization |
| WTO | World Trade Organization |
Table of contents
Share
Facebook
Twitter
LinkedIn